-

Monsanto Wins Appeal Ruling in Erickson v. Monsanto

Court remands PCB case back to trial court for further proceedings

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, a decision was issued by the Court of Appeals Division I in the State of Washington in Erickson v. Monsanto, ruling in Monsanto’s favor on multiple grounds.

This decision reverses the initial verdict of $185 million in its entirety and remands the case back to trial court for further proceedings.

The company stated:

“This is a very significant ruling in favor of Monsanto because the Court of Appeals identified multiple errors - that cut across most Sky Valley Education Center (SVEC) trials that have been completed - including the unreliability of Plaintiffs’ exposure evidence that was erroneously admitted in all SVEC cases tried to date. Specifically, the Court of Appeals held that the trial court improperly denied the Company’s statute of repose defense, erroneously admitted a major portion of plaintiffs’ key expert exposure opinions, and wrongfully allowed punitive damages on plaintiffs’ post-sale failure to warn.

“The Company will consider its legal options regarding the application of this ruling to other SVEC verdicts that are in conflict with it, as well as how this ruling could affect future trials.”

The SVEC cases represent most of PCB-related personal injury litigation against Monsanto. Erickson is the first personal injury case to go to trial due to alleged PCB exposure at a single school in Washington state.

The evidence in these cases have demonstrated that all measured PCB air concentrations at SVEC fell well below the regulatory health-protective limits and guidelines set by state and federal regulators, and there is no evidence any such exposure to PCBs can and did cause the alleged injuries.

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

Media Alert for Durnell Supreme Court Argument

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--On April 27th, Monsanto will argue before the U.S. Supreme Court in Durnell v. Monsanto, a Roundup case involving the application of federal preemption under FIFRA. A favorable ruling by the Supreme Court would provide essential regulatory clarity for companies who seek to bring currently approved and new products to market, addressing their ability to serve U.S. farmers and consumers. Former Solicitor General Paul Clement will argue the case fo...

Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential

BERLIN--(BUSINESS WIRE)--Bayer today announced a leadership change within its Pharmaceuticals’ Worldwide Markets organization to accelerate the strong performance and growth of its key pharmaceutical products in the U.S. Effective May 1, 2026, Nelson Ambrogio, currently President of Bayer’s global Radiology business, will be appointed President of Bayer U.S. Pharmaceuticals. Nelson Ambrogio will guide the U.S. Pharmaceuticals organization into its next chapter of growth and build on the strong...

Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris

WHIPPANY, N.J.--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand from Bayer backed by more than 80 years of nutritional science, today announced a partnership with Grammy Award winning recording artist, actor and philanthropist Ludacris. The collaboration brings together two names with a shared commitment to simplicity, consistency, and staying power—demonstrating how effortlessly consumers can support their health in a straightforward way with One A Day®. What is the new camp...
Back to Newsroom